nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexamethasone—CYP2E1—liver cancer	0.155	0.503	CbGaD
Dexamethasone—CYP1A1—liver cancer	0.153	0.497	CbGaD
Dexamethasone—NOS2—Doxorubicin—liver cancer	0.13	0.31	CbGbCtD
Dexamethasone—CYP1B1—Doxorubicin—liver cancer	0.0311	0.0739	CbGbCtD
Dexamethasone—ABCB11—Doxorubicin—liver cancer	0.0311	0.0739	CbGbCtD
Dexamethasone—ABCC2—Sorafenib—liver cancer	0.0269	0.064	CbGbCtD
Dexamethasone—ABCB11—bile canaliculus—liver cancer	0.0268	0.355	CbGeAlD
Dexamethasone—ABCG2—Sorafenib—liver cancer	0.0243	0.0579	CbGbCtD
Dexamethasone—CYP3A7—Sorafenib—liver cancer	0.018	0.0427	CbGbCtD
Dexamethasone—CYP3A7-CYP3A51P—Sorafenib—liver cancer	0.018	0.0427	CbGbCtD
Dexamethasone—CYP2B6—Sorafenib—liver cancer	0.0171	0.0407	CbGbCtD
Dexamethasone—ABCC2—Doxorubicin—liver cancer	0.0163	0.0388	CbGbCtD
Dexamethasone—ABCG2—Doxorubicin—liver cancer	0.0148	0.0351	CbGbCtD
Dexamethasone—ABCC2—bile canaliculus—liver cancer	0.0136	0.181	CbGeAlD
Dexamethasone—CYP3A5—Sorafenib—liver cancer	0.0135	0.0321	CbGbCtD
Dexamethasone—CYP2C8—Sorafenib—liver cancer	0.013	0.0308	CbGbCtD
Dexamethasone—CYP2C19—Sorafenib—liver cancer	0.0109	0.0259	CbGbCtD
Dexamethasone—CYP2B6—Doxorubicin—liver cancer	0.0104	0.0247	CbGbCtD
Dexamethasone—CYP2C9—Sorafenib—liver cancer	0.00904	0.0215	CbGbCtD
Dexamethasone—ABCB1—Sorafenib—liver cancer	0.00877	0.0209	CbGbCtD
Dexamethasone—ABCB11—bile duct—liver cancer	0.00837	0.111	CbGeAlD
Dexamethasone—CYP2D6—Sorafenib—liver cancer	0.00827	0.0197	CbGbCtD
Dexamethasone—ABCB11—bile—liver cancer	0.00643	0.0852	CbGeAlD
Dexamethasone—ABCB1—Doxorubicin—liver cancer	0.00532	0.0127	CbGbCtD
Dexamethasone—CYP3A4—Sorafenib—liver cancer	0.00526	0.0125	CbGbCtD
Dexamethasone—CYP2D6—Doxorubicin—liver cancer	0.00502	0.0119	CbGbCtD
Dexamethasone—ABCC2—bile duct—liver cancer	0.00426	0.0564	CbGeAlD
Dexamethasone—ABCC2—bile—liver cancer	0.00327	0.0433	CbGeAlD
Dexamethasone—CYP3A4—Doxorubicin—liver cancer	0.00319	0.00759	CbGbCtD
Dexamethasone—ANXA1—gall bladder—liver cancer	0.00176	0.0233	CbGeAlD
Dexamethasone—CYP3A43—liver—liver cancer	0.00114	0.0151	CbGeAlD
Dexamethasone—ANXA1—embryo—liver cancer	0.00111	0.0147	CbGeAlD
Dexamethasone—CYP4A11—liver—liver cancer	0.000812	0.0108	CbGeAlD
Dexamethasone—PTGS2—gall bladder—liver cancer	0.000528	0.00699	CbGeAlD
Dexamethasone—ABCB11—liver—liver cancer	0.000524	0.00694	CbGeAlD
Dexamethasone—ANXA1—liver—liver cancer	0.000515	0.00682	CbGeAlD
Dexamethasone—CYP3A7—liver—liver cancer	0.000512	0.00678	CbGeAlD
Dexamethasone—Embolism venous—Doxorubicin—liver cancer	0.000464	0.00695	CcSEcCtD
Dexamethasone—CYP17A1—liver—liver cancer	0.000461	0.00611	CbGeAlD
Dexamethasone—Blindness—Epirubicin—liver cancer	0.000457	0.00684	CcSEcCtD
Dexamethasone—Dry skin—Sorafenib—liver cancer	0.000456	0.00682	CcSEcCtD
Dexamethasone—Hypokalaemia—Sorafenib—liver cancer	0.000453	0.00677	CcSEcCtD
Dexamethasone—Hypernatraemia—Doxorubicin—liver cancer	0.000446	0.00667	CcSEcCtD
Dexamethasone—CYP3A7-CYP3A51P—liver—liver cancer	0.000435	0.00577	CbGeAlD
Dexamethasone—Skin hyperpigmentation—Epirubicin—liver cancer	0.000426	0.00637	CcSEcCtD
Dexamethasone—Blindness—Doxorubicin—liver cancer	0.000423	0.00633	CcSEcCtD
Dexamethasone—Optic neuritis—Epirubicin—liver cancer	0.000412	0.00616	CcSEcCtD
Dexamethasone—Folliculitis—Epirubicin—liver cancer	0.000403	0.00603	CcSEcCtD
Dexamethasone—Embolism—Epirubicin—liver cancer	0.000395	0.0059	CcSEcCtD
Dexamethasone—Skin hyperpigmentation—Doxorubicin—liver cancer	0.000394	0.00589	CcSEcCtD
Dexamethasone—Keratitis—Epirubicin—liver cancer	0.000391	0.00584	CcSEcCtD
Dexamethasone—Weight decreased—Sorafenib—liver cancer	0.000389	0.00582	CcSEcCtD
Dexamethasone—NR3C1—embryo—liver cancer	0.000387	0.00512	CbGeAlD
Dexamethasone—Optic neuritis—Doxorubicin—liver cancer	0.000381	0.0057	CcSEcCtD
Dexamethasone—Acute coronary syndrome—Sorafenib—liver cancer	0.000378	0.00565	CcSEcCtD
Dexamethasone—Myocardial infarction—Sorafenib—liver cancer	0.000376	0.00562	CcSEcCtD
Dexamethasone—Neuropathy peripheral—Sorafenib—liver cancer	0.000376	0.00562	CcSEcCtD
Dexamethasone—Folliculitis—Doxorubicin—liver cancer	0.000373	0.00558	CcSEcCtD
Dexamethasone—Embolism—Doxorubicin—liver cancer	0.000365	0.00546	CcSEcCtD
Dexamethasone—Keratitis—Doxorubicin—liver cancer	0.000361	0.00541	CcSEcCtD
Dexamethasone—Hepatomegaly—Epirubicin—liver cancer	0.000358	0.00535	CcSEcCtD
Dexamethasone—CYP2A6—liver—liver cancer	0.000356	0.00471	CbGeAlD
Dexamethasone—Blister—Epirubicin—liver cancer	0.000351	0.00526	CcSEcCtD
Dexamethasone—Haemoglobin—Sorafenib—liver cancer	0.000346	0.00518	CcSEcCtD
Dexamethasone—Haemorrhage—Sorafenib—liver cancer	0.000344	0.00515	CcSEcCtD
Dexamethasone—Neuritis—Epirubicin—liver cancer	0.000339	0.00508	CcSEcCtD
Dexamethasone—PTGS2—embryo—liver cancer	0.000335	0.00443	CbGeAlD
Dexamethasone—NR3C2—liver—liver cancer	0.000333	0.00442	CbGeAlD
Dexamethasone—Hepatomegaly—Doxorubicin—liver cancer	0.000331	0.00495	CcSEcCtD
Dexamethasone—Rash erythematous—Epirubicin—liver cancer	0.000331	0.00495	CcSEcCtD
Dexamethasone—Fungal infection—Epirubicin—liver cancer	0.000328	0.00491	CcSEcCtD
Dexamethasone—Blister—Doxorubicin—liver cancer	0.000325	0.00486	CcSEcCtD
Dexamethasone—Necrosis—Epirubicin—liver cancer	0.000323	0.00483	CcSEcCtD
Dexamethasone—Abscess—Epirubicin—liver cancer	0.00032	0.00479	CcSEcCtD
Dexamethasone—Neuritis—Doxorubicin—liver cancer	0.000314	0.0047	CcSEcCtD
Dexamethasone—Stinging—Epirubicin—liver cancer	0.000313	0.00468	CcSEcCtD
Dexamethasone—Glycosuria—Epirubicin—liver cancer	0.000313	0.00468	CcSEcCtD
Dexamethasone—Angiopathy—Sorafenib—liver cancer	0.000312	0.00467	CcSEcCtD
Dexamethasone—Petechiae—Epirubicin—liver cancer	0.000308	0.00461	CcSEcCtD
Dexamethasone—Arrhythmia—Sorafenib—liver cancer	0.000307	0.0046	CcSEcCtD
Dexamethasone—Rash erythematous—Doxorubicin—liver cancer	0.000306	0.00458	CcSEcCtD
Dexamethasone—Alopecia—Sorafenib—liver cancer	0.000304	0.00455	CcSEcCtD
Dexamethasone—Fungal infection—Doxorubicin—liver cancer	0.000304	0.00454	CcSEcCtD
Dexamethasone—Erythema—Sorafenib—liver cancer	0.0003	0.00448	CcSEcCtD
Dexamethasone—Necrosis—Doxorubicin—liver cancer	0.000299	0.00447	CcSEcCtD
Dexamethasone—Abscess—Doxorubicin—liver cancer	0.000296	0.00443	CcSEcCtD
Dexamethasone—Extravasation—Epirubicin—liver cancer	0.00029	0.00434	CcSEcCtD
Dexamethasone—Stinging—Doxorubicin—liver cancer	0.000289	0.00433	CcSEcCtD
Dexamethasone—Glycosuria—Doxorubicin—liver cancer	0.000289	0.00433	CcSEcCtD
Dexamethasone—Amenorrhoea—Epirubicin—liver cancer	0.000288	0.00431	CcSEcCtD
Dexamethasone—SLCO1A2—liver—liver cancer	0.000286	0.00379	CbGeAlD
Dexamethasone—Petechiae—Doxorubicin—liver cancer	0.000285	0.00426	CcSEcCtD
Dexamethasone—CYP19A1—liver—liver cancer	0.000279	0.0037	CbGeAlD
Dexamethasone—Arthropathy—Epirubicin—liver cancer	0.000279	0.00417	CcSEcCtD
Dexamethasone—Herpes simplex—Epirubicin—liver cancer	0.000275	0.00411	CcSEcCtD
Dexamethasone—Angioedema—Sorafenib—liver cancer	0.000274	0.0041	CcSEcCtD
Dexamethasone—Syncope—Sorafenib—liver cancer	0.000269	0.00402	CcSEcCtD
Dexamethasone—Extravasation—Doxorubicin—liver cancer	0.000269	0.00402	CcSEcCtD
Dexamethasone—Ulcer—Epirubicin—liver cancer	0.000268	0.00401	CcSEcCtD
Dexamethasone—Amenorrhoea—Doxorubicin—liver cancer	0.000267	0.00399	CcSEcCtD
Dexamethasone—ABCC2—liver—liver cancer	0.000266	0.00353	CbGeAlD
Dexamethasone—Loss of consciousness—Sorafenib—liver cancer	0.000263	0.00394	CcSEcCtD
Dexamethasone—CYP1B1—liver—liver cancer	0.000261	0.00345	CbGeAlD
Dexamethasone—Hypertension—Sorafenib—liver cancer	0.000259	0.00387	CcSEcCtD
Dexamethasone—Arthropathy—Doxorubicin—liver cancer	0.000258	0.00386	CcSEcCtD
Dexamethasone—Myalgia—Sorafenib—liver cancer	0.000255	0.00382	CcSEcCtD
Dexamethasone—Herpes simplex—Doxorubicin—liver cancer	0.000254	0.0038	CcSEcCtD
Dexamethasone—Hiccups—Epirubicin—liver cancer	0.000253	0.00379	CcSEcCtD
Dexamethasone—Dermatitis contact—Epirubicin—liver cancer	0.00025	0.00374	CcSEcCtD
Dexamethasone—Ulcer—Doxorubicin—liver cancer	0.000248	0.00371	CcSEcCtD
Dexamethasone—Anaphylactic shock—Sorafenib—liver cancer	0.000245	0.00366	CcSEcCtD
Dexamethasone—Infection—Sorafenib—liver cancer	0.000243	0.00363	CcSEcCtD
Dexamethasone—Skin exfoliation—Epirubicin—liver cancer	0.000242	0.00362	CcSEcCtD
Dexamethasone—Shock—Sorafenib—liver cancer	0.000241	0.0036	CcSEcCtD
Dexamethasone—Fluid retention—Epirubicin—liver cancer	0.00024	0.0036	CcSEcCtD
Dexamethasone—Nervous system disorder—Sorafenib—liver cancer	0.00024	0.00359	CcSEcCtD
Dexamethasone—Thrombocytopenia—Sorafenib—liver cancer	0.000239	0.00358	CcSEcCtD
Dexamethasone—Neuropathy—Epirubicin—liver cancer	0.000238	0.00356	CcSEcCtD
Dexamethasone—Hiccups—Doxorubicin—liver cancer	0.000234	0.00351	CcSEcCtD
Dexamethasone—Dry eye—Epirubicin—liver cancer	0.000234	0.0035	CcSEcCtD
Dexamethasone—Anorexia—Sorafenib—liver cancer	0.000233	0.00349	CcSEcCtD
Dexamethasone—Dermatitis contact—Doxorubicin—liver cancer	0.000232	0.00347	CcSEcCtD
Dexamethasone—Oesophagitis—Epirubicin—liver cancer	0.000231	0.00346	CcSEcCtD
Dexamethasone—Ecchymosis—Epirubicin—liver cancer	0.000229	0.00343	CcSEcCtD
Dexamethasone—CYP2C19—liver—liver cancer	0.000229	0.00303	CbGeAlD
Dexamethasone—Pulmonary oedema—Epirubicin—liver cancer	0.000225	0.00337	CcSEcCtD
Dexamethasone—Skin exfoliation—Doxorubicin—liver cancer	0.000224	0.00335	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000223	0.00333	CcSEcCtD
Dexamethasone—Fluid retention—Doxorubicin—liver cancer	0.000222	0.00333	CcSEcCtD
Dexamethasone—Neuropathy—Doxorubicin—liver cancer	0.00022	0.00329	CcSEcCtD
Dexamethasone—Dry eye—Doxorubicin—liver cancer	0.000216	0.00324	CcSEcCtD
Dexamethasone—Dyspepsia—Sorafenib—liver cancer	0.000215	0.00322	CcSEcCtD
Dexamethasone—Oesophagitis—Doxorubicin—liver cancer	0.000214	0.0032	CcSEcCtD
Dexamethasone—Decreased appetite—Sorafenib—liver cancer	0.000213	0.00318	CcSEcCtD
Dexamethasone—Thrombophlebitis—Epirubicin—liver cancer	0.000212	0.00318	CcSEcCtD
Dexamethasone—Ecchymosis—Doxorubicin—liver cancer	0.000212	0.00317	CcSEcCtD
Dexamethasone—Diabetes mellitus—Epirubicin—liver cancer	0.000211	0.00316	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Sorafenib—liver cancer	0.000211	0.00316	CcSEcCtD
Dexamethasone—Fatigue—Sorafenib—liver cancer	0.000211	0.00315	CcSEcCtD
Dexamethasone—Pain—Sorafenib—liver cancer	0.000209	0.00313	CcSEcCtD
Dexamethasone—Pulmonary oedema—Doxorubicin—liver cancer	0.000209	0.00312	CcSEcCtD
Dexamethasone—ABCB1—embryo—liver cancer	0.000207	0.00274	CbGeAlD
Dexamethasone—Eye pain—Epirubicin—liver cancer	0.000204	0.00305	CcSEcCtD
Dexamethasone—Cardiac failure congestive—Epirubicin—liver cancer	0.000203	0.00303	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Sorafenib—liver cancer	0.0002	0.00299	CcSEcCtD
Dexamethasone—CYP2C8—liver—liver cancer	0.0002	0.00265	CbGeAlD
Dexamethasone—Thrombophlebitis—Doxorubicin—liver cancer	0.000197	0.00294	CcSEcCtD
Dexamethasone—Increased appetite—Epirubicin—liver cancer	0.000196	0.00293	CcSEcCtD
Dexamethasone—Diabetes mellitus—Doxorubicin—liver cancer	0.000196	0.00293	CcSEcCtD
Dexamethasone—Urticaria—Sorafenib—liver cancer	0.000194	0.00291	CcSEcCtD
Dexamethasone—ABCG2—liver—liver cancer	0.000194	0.00257	CbGeAlD
Dexamethasone—Body temperature increased—Sorafenib—liver cancer	0.000193	0.00289	CcSEcCtD
Dexamethasone—Abdominal pain—Sorafenib—liver cancer	0.000193	0.00289	CcSEcCtD
Dexamethasone—Dermatitis bullous—Epirubicin—liver cancer	0.000192	0.00288	CcSEcCtD
Dexamethasone—Anaphylactoid reaction—Epirubicin—liver cancer	0.00019	0.00284	CcSEcCtD
Dexamethasone—Eye pain—Doxorubicin—liver cancer	0.000188	0.00282	CcSEcCtD
Dexamethasone—Cardiac failure—Epirubicin—liver cancer	0.000188	0.00282	CcSEcCtD
Dexamethasone—Lethargy—Epirubicin—liver cancer	0.000188	0.00281	CcSEcCtD
Dexamethasone—Cardiac failure congestive—Doxorubicin—liver cancer	0.000188	0.00281	CcSEcCtD
Dexamethasone—CYP1A1—liver—liver cancer	0.000184	0.00244	CbGeAlD
Dexamethasone—Osteoarthritis—Epirubicin—liver cancer	0.000184	0.00275	CcSEcCtD
Dexamethasone—Increased appetite—Doxorubicin—liver cancer	0.000181	0.00271	CcSEcCtD
Dexamethasone—Affect lability—Epirubicin—liver cancer	0.000181	0.00271	CcSEcCtD
Dexamethasone—Migraine—Epirubicin—liver cancer	0.000181	0.00271	CcSEcCtD
Dexamethasone—CYP3A5—liver—liver cancer	0.00018	0.00239	CbGeAlD
Dexamethasone—CYP2B6—liver—liver cancer	0.000179	0.00237	CbGeAlD
Dexamethasone—NR3C1—liver—liver cancer	0.000179	0.00237	CbGeAlD
Dexamethasone—Dermatitis bullous—Doxorubicin—liver cancer	0.000178	0.00266	CcSEcCtD
Dexamethasone—CYP2C9—liver—liver cancer	0.000177	0.00235	CbGeAlD
Dexamethasone—Anaphylactoid reaction—Doxorubicin—liver cancer	0.000176	0.00263	CcSEcCtD
Dexamethasone—Asthenia—Sorafenib—liver cancer	0.000175	0.00262	CcSEcCtD
Dexamethasone—Cardiac arrest—Epirubicin—liver cancer	0.000175	0.00262	CcSEcCtD
Dexamethasone—Cardiac failure—Doxorubicin—liver cancer	0.000174	0.00261	CcSEcCtD
Dexamethasone—Mood swings—Epirubicin—liver cancer	0.000174	0.00261	CcSEcCtD
Dexamethasone—Lethargy—Doxorubicin—liver cancer	0.000174	0.0026	CcSEcCtD
Dexamethasone—Pruritus—Sorafenib—liver cancer	0.000173	0.00259	CcSEcCtD
Dexamethasone—Osteoarthritis—Doxorubicin—liver cancer	0.00017	0.00255	CcSEcCtD
Dexamethasone—Dry skin—Epirubicin—liver cancer	0.000169	0.00252	CcSEcCtD
Dexamethasone—CYP2E1—liver—liver cancer	0.000168	0.00223	CbGeAlD
Dexamethasone—Affect lability—Doxorubicin—liver cancer	0.000167	0.00251	CcSEcCtD
Dexamethasone—Migraine—Doxorubicin—liver cancer	0.000167	0.00251	CcSEcCtD
Dexamethasone—Hypokalaemia—Epirubicin—liver cancer	0.000167	0.0025	CcSEcCtD
Dexamethasone—Diarrhoea—Sorafenib—liver cancer	0.000167	0.0025	CcSEcCtD
Dexamethasone—Muscular weakness—Epirubicin—liver cancer	0.000162	0.00243	CcSEcCtD
Dexamethasone—Cardiac arrest—Doxorubicin—liver cancer	0.000162	0.00242	CcSEcCtD
Dexamethasone—Dizziness—Sorafenib—liver cancer	0.000162	0.00242	CcSEcCtD
Dexamethasone—Mood swings—Doxorubicin—liver cancer	0.000161	0.00241	CcSEcCtD
Dexamethasone—Dry skin—Doxorubicin—liver cancer	0.000156	0.00233	CcSEcCtD
Dexamethasone—Vomiting—Sorafenib—liver cancer	0.000155	0.00233	CcSEcCtD
Dexamethasone—Hypokalaemia—Doxorubicin—liver cancer	0.000155	0.00232	CcSEcCtD
Dexamethasone—PTGS2—liver—liver cancer	0.000155	0.00205	CbGeAlD
Dexamethasone—Rash—Sorafenib—liver cancer	0.000154	0.00231	CcSEcCtD
Dexamethasone—Dermatitis—Sorafenib—liver cancer	0.000154	0.0023	CcSEcCtD
Dexamethasone—Headache—Sorafenib—liver cancer	0.000153	0.00229	CcSEcCtD
Dexamethasone—Muscular weakness—Doxorubicin—liver cancer	0.00015	0.00224	CcSEcCtD
Dexamethasone—Nausea—Sorafenib—liver cancer	0.000145	0.00217	CcSEcCtD
Dexamethasone—Weight increased—Epirubicin—liver cancer	0.000145	0.00216	CcSEcCtD
Dexamethasone—Weight decreased—Epirubicin—liver cancer	0.000144	0.00215	CcSEcCtD
Dexamethasone—Hyperglycaemia—Epirubicin—liver cancer	0.000143	0.00214	CcSEcCtD
Dexamethasone—Neuropathy peripheral—Epirubicin—liver cancer	0.000139	0.00208	CcSEcCtD
Dexamethasone—Conjunctivitis—Epirubicin—liver cancer	0.000138	0.00206	CcSEcCtD
Dexamethasone—CYP3A4—liver—liver cancer	0.000135	0.00179	CbGeAlD
Dexamethasone—Weight increased—Doxorubicin—liver cancer	0.000134	0.002	CcSEcCtD
Dexamethasone—CYP2D6—liver—liver cancer	0.000133	0.00176	CbGeAlD
Dexamethasone—Weight decreased—Doxorubicin—liver cancer	0.000133	0.00199	CcSEcCtD
Dexamethasone—Hyperglycaemia—Doxorubicin—liver cancer	0.000133	0.00198	CcSEcCtD
Dexamethasone—Bradycardia—Epirubicin—liver cancer	0.000129	0.00194	CcSEcCtD
Dexamethasone—Neuropathy peripheral—Doxorubicin—liver cancer	0.000129	0.00192	CcSEcCtD
Dexamethasone—Haemoglobin—Epirubicin—liver cancer	0.000128	0.00191	CcSEcCtD
Dexamethasone—Conjunctivitis—Doxorubicin—liver cancer	0.000127	0.00191	CcSEcCtD
Dexamethasone—Haemorrhage—Epirubicin—liver cancer	0.000127	0.0019	CcSEcCtD
Dexamethasone—Visual impairment—Epirubicin—liver cancer	0.000123	0.00183	CcSEcCtD
Dexamethasone—Bradycardia—Doxorubicin—liver cancer	0.00012	0.00179	CcSEcCtD
Dexamethasone—Eye disorder—Epirubicin—liver cancer	0.000119	0.00178	CcSEcCtD
Dexamethasone—Haemoglobin—Doxorubicin—liver cancer	0.000118	0.00177	CcSEcCtD
Dexamethasone—Haemorrhage—Doxorubicin—liver cancer	0.000118	0.00176	CcSEcCtD
Dexamethasone—Angiopathy—Epirubicin—liver cancer	0.000115	0.00173	CcSEcCtD
Dexamethasone—Arrhythmia—Epirubicin—liver cancer	0.000114	0.0017	CcSEcCtD
Dexamethasone—Visual impairment—Doxorubicin—liver cancer	0.000113	0.0017	CcSEcCtD
Dexamethasone—Alopecia—Epirubicin—liver cancer	0.000112	0.00168	CcSEcCtD
Dexamethasone—Erythema—Epirubicin—liver cancer	0.000111	0.00166	CcSEcCtD
Dexamethasone—Eye disorder—Doxorubicin—liver cancer	0.00011	0.00165	CcSEcCtD
Dexamethasone—Angiopathy—Doxorubicin—liver cancer	0.000107	0.0016	CcSEcCtD
Dexamethasone—Arrhythmia—Doxorubicin—liver cancer	0.000105	0.00157	CcSEcCtD
Dexamethasone—Alopecia—Doxorubicin—liver cancer	0.000104	0.00156	CcSEcCtD
Dexamethasone—Ill-defined disorder—Epirubicin—liver cancer	0.000103	0.00154	CcSEcCtD
Dexamethasone—Erythema—Doxorubicin—liver cancer	0.000102	0.00153	CcSEcCtD
Dexamethasone—Malaise—Epirubicin—liver cancer	9.99e-05	0.00149	CcSEcCtD
Dexamethasone—Vertigo—Epirubicin—liver cancer	9.95e-05	0.00149	CcSEcCtD
Dexamethasone—Syncope—Epirubicin—liver cancer	9.93e-05	0.00149	CcSEcCtD
Dexamethasone—Loss of consciousness—Epirubicin—liver cancer	9.73e-05	0.00146	CcSEcCtD
Dexamethasone—Convulsion—Epirubicin—liver cancer	9.59e-05	0.00144	CcSEcCtD
Dexamethasone—ABCB1—liver—liver cancer	9.57e-05	0.00127	CbGeAlD
Dexamethasone—Hypertension—Epirubicin—liver cancer	9.56e-05	0.00143	CcSEcCtD
Dexamethasone—Ill-defined disorder—Doxorubicin—liver cancer	9.51e-05	0.00142	CcSEcCtD
Dexamethasone—Myalgia—Epirubicin—liver cancer	9.43e-05	0.00141	CcSEcCtD
Dexamethasone—Anxiety—Epirubicin—liver cancer	9.39e-05	0.00141	CcSEcCtD
Dexamethasone—Discomfort—Epirubicin—liver cancer	9.31e-05	0.00139	CcSEcCtD
Dexamethasone—Malaise—Doxorubicin—liver cancer	9.24e-05	0.00138	CcSEcCtD
Dexamethasone—Vertigo—Doxorubicin—liver cancer	9.2e-05	0.00138	CcSEcCtD
Dexamethasone—Syncope—Doxorubicin—liver cancer	9.19e-05	0.00137	CcSEcCtD
Dexamethasone—Oedema—Epirubicin—liver cancer	9.04e-05	0.00135	CcSEcCtD
Dexamethasone—Anaphylactic shock—Epirubicin—liver cancer	9.04e-05	0.00135	CcSEcCtD
Dexamethasone—Loss of consciousness—Doxorubicin—liver cancer	9e-05	0.00135	CcSEcCtD
Dexamethasone—Infection—Epirubicin—liver cancer	8.98e-05	0.00134	CcSEcCtD
Dexamethasone—Shock—Epirubicin—liver cancer	8.89e-05	0.00133	CcSEcCtD
Dexamethasone—Convulsion—Doxorubicin—liver cancer	8.88e-05	0.00133	CcSEcCtD
Dexamethasone—Nervous system disorder—Epirubicin—liver cancer	8.86e-05	0.00133	CcSEcCtD
Dexamethasone—Thrombocytopenia—Epirubicin—liver cancer	8.85e-05	0.00132	CcSEcCtD
Dexamethasone—Hypertension—Doxorubicin—liver cancer	8.85e-05	0.00132	CcSEcCtD
Dexamethasone—Tachycardia—Epirubicin—liver cancer	8.82e-05	0.00132	CcSEcCtD
Dexamethasone—Hyperhidrosis—Epirubicin—liver cancer	8.74e-05	0.00131	CcSEcCtD
Dexamethasone—Myalgia—Doxorubicin—liver cancer	8.72e-05	0.0013	CcSEcCtD
Dexamethasone—Anxiety—Doxorubicin—liver cancer	8.69e-05	0.0013	CcSEcCtD
Dexamethasone—Discomfort—Doxorubicin—liver cancer	8.62e-05	0.00129	CcSEcCtD
Dexamethasone—Anorexia—Epirubicin—liver cancer	8.61e-05	0.00129	CcSEcCtD
Dexamethasone—Hypotension—Epirubicin—liver cancer	8.44e-05	0.00126	CcSEcCtD
Dexamethasone—Anaphylactic shock—Doxorubicin—liver cancer	8.36e-05	0.00125	CcSEcCtD
Dexamethasone—Oedema—Doxorubicin—liver cancer	8.36e-05	0.00125	CcSEcCtD
Dexamethasone—Infection—Doxorubicin—liver cancer	8.31e-05	0.00124	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Epirubicin—liver cancer	8.23e-05	0.00123	CcSEcCtD
Dexamethasone—Shock—Doxorubicin—liver cancer	8.23e-05	0.00123	CcSEcCtD
Dexamethasone—Nervous system disorder—Doxorubicin—liver cancer	8.2e-05	0.00123	CcSEcCtD
Dexamethasone—Thrombocytopenia—Doxorubicin—liver cancer	8.19e-05	0.00122	CcSEcCtD
Dexamethasone—Insomnia—Epirubicin—liver cancer	8.17e-05	0.00122	CcSEcCtD
Dexamethasone—Tachycardia—Doxorubicin—liver cancer	8.16e-05	0.00122	CcSEcCtD
Dexamethasone—Paraesthesia—Epirubicin—liver cancer	8.11e-05	0.00121	CcSEcCtD
Dexamethasone—Hyperhidrosis—Doxorubicin—liver cancer	8.08e-05	0.00121	CcSEcCtD
Dexamethasone—Anorexia—Doxorubicin—liver cancer	7.97e-05	0.00119	CcSEcCtD
Dexamethasone—Dyspepsia—Epirubicin—liver cancer	7.95e-05	0.00119	CcSEcCtD
Dexamethasone—Decreased appetite—Epirubicin—liver cancer	7.86e-05	0.00118	CcSEcCtD
Dexamethasone—Hypotension—Doxorubicin—liver cancer	7.81e-05	0.00117	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Epirubicin—liver cancer	7.8e-05	0.00117	CcSEcCtD
Dexamethasone—Fatigue—Epirubicin—liver cancer	7.79e-05	0.00117	CcSEcCtD
Dexamethasone—Pain—Epirubicin—liver cancer	7.73e-05	0.00116	CcSEcCtD
Dexamethasone—Musculoskeletal discomfort—Doxorubicin—liver cancer	7.62e-05	0.00114	CcSEcCtD
Dexamethasone—Insomnia—Doxorubicin—liver cancer	7.56e-05	0.00113	CcSEcCtD
Dexamethasone—Paraesthesia—Doxorubicin—liver cancer	7.51e-05	0.00112	CcSEcCtD
Dexamethasone—Feeling abnormal—Epirubicin—liver cancer	7.45e-05	0.00111	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Epirubicin—liver cancer	7.39e-05	0.00111	CcSEcCtD
Dexamethasone—Dyspepsia—Doxorubicin—liver cancer	7.36e-05	0.0011	CcSEcCtD
Dexamethasone—Decreased appetite—Doxorubicin—liver cancer	7.27e-05	0.00109	CcSEcCtD
Dexamethasone—Gastrointestinal disorder—Doxorubicin—liver cancer	7.22e-05	0.00108	CcSEcCtD
Dexamethasone—Fatigue—Doxorubicin—liver cancer	7.21e-05	0.00108	CcSEcCtD
Dexamethasone—Urticaria—Epirubicin—liver cancer	7.18e-05	0.00107	CcSEcCtD
Dexamethasone—Pain—Doxorubicin—liver cancer	7.15e-05	0.00107	CcSEcCtD
Dexamethasone—Abdominal pain—Epirubicin—liver cancer	7.14e-05	0.00107	CcSEcCtD
Dexamethasone—Body temperature increased—Epirubicin—liver cancer	7.14e-05	0.00107	CcSEcCtD
Dexamethasone—Feeling abnormal—Doxorubicin—liver cancer	6.89e-05	0.00103	CcSEcCtD
Dexamethasone—Gastrointestinal pain—Doxorubicin—liver cancer	6.84e-05	0.00102	CcSEcCtD
Dexamethasone—Urticaria—Doxorubicin—liver cancer	6.64e-05	0.000994	CcSEcCtD
Dexamethasone—Abdominal pain—Doxorubicin—liver cancer	6.61e-05	0.000989	CcSEcCtD
Dexamethasone—Body temperature increased—Doxorubicin—liver cancer	6.61e-05	0.000989	CcSEcCtD
Dexamethasone—Asthenia—Epirubicin—liver cancer	6.48e-05	0.00097	CcSEcCtD
Dexamethasone—Pruritus—Epirubicin—liver cancer	6.39e-05	0.000957	CcSEcCtD
Dexamethasone—Diarrhoea—Epirubicin—liver cancer	6.18e-05	0.000925	CcSEcCtD
Dexamethasone—Asthenia—Doxorubicin—liver cancer	6e-05	0.000898	CcSEcCtD
Dexamethasone—Dizziness—Epirubicin—liver cancer	5.98e-05	0.000894	CcSEcCtD
Dexamethasone—Pruritus—Doxorubicin—liver cancer	5.92e-05	0.000885	CcSEcCtD
Dexamethasone—Vomiting—Epirubicin—liver cancer	5.75e-05	0.00086	CcSEcCtD
Dexamethasone—Diarrhoea—Doxorubicin—liver cancer	5.72e-05	0.000856	CcSEcCtD
Dexamethasone—Rash—Epirubicin—liver cancer	5.7e-05	0.000852	CcSEcCtD
Dexamethasone—Dermatitis—Epirubicin—liver cancer	5.69e-05	0.000852	CcSEcCtD
Dexamethasone—Headache—Epirubicin—liver cancer	5.66e-05	0.000847	CcSEcCtD
Dexamethasone—Dizziness—Doxorubicin—liver cancer	5.53e-05	0.000827	CcSEcCtD
Dexamethasone—Nausea—Epirubicin—liver cancer	5.37e-05	0.000803	CcSEcCtD
Dexamethasone—Vomiting—Doxorubicin—liver cancer	5.32e-05	0.000795	CcSEcCtD
Dexamethasone—Rash—Doxorubicin—liver cancer	5.27e-05	0.000789	CcSEcCtD
Dexamethasone—Dermatitis—Doxorubicin—liver cancer	5.27e-05	0.000788	CcSEcCtD
Dexamethasone—Headache—Doxorubicin—liver cancer	5.24e-05	0.000784	CcSEcCtD
Dexamethasone—Nausea—Doxorubicin—liver cancer	4.97e-05	0.000743	CcSEcCtD
Dexamethasone—Fluoxymesterone—ESR1—liver cancer	1.43e-05	0.425	CrCbGaD
Dexamethasone—Clobetasol propionate—CYP1A1—liver cancer	1.39e-05	0.412	CrCbGaD
Dexamethasone—Prednisone—ALB—liver cancer	5.51e-06	0.163	CrCbGaD
Dexamethasone—CYP2D6—Metabolism—PSMD10—liver cancer	3.12e-06	2.41e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CTNNB1—liver cancer	3.12e-06	2.41e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—GSTM1—liver cancer	3.11e-06	2.4e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CYP2E1—liver cancer	3.1e-06	2.4e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	3.1e-06	2.4e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PSMA4—liver cancer	3.09e-06	2.39e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PSMD10—liver cancer	3.09e-06	2.39e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—HMOX1—liver cancer	3.08e-06	2.38e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GSTA4—liver cancer	3.08e-06	2.38e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—CYP1A1—liver cancer	3.07e-06	2.37e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MMP9—liver cancer	3.06e-06	2.36e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PIK3CB—liver cancer	3.05e-06	2.36e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—GSTM1—liver cancer	3.05e-06	2.35e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PIK3CD—liver cancer	3.05e-06	2.35e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—CDKN1A—liver cancer	3.05e-06	2.35e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PPARG—liver cancer	3.04e-06	2.35e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—GSTM1—liver cancer	3.04e-06	2.35e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GOT2—liver cancer	3.04e-06	2.34e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CYP2E1—liver cancer	3.03e-06	2.34e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PPARG—liver cancer	3.02e-06	2.33e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GOT2—liver cancer	3.01e-06	2.32e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—ALB—liver cancer	3.01e-06	2.32e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3e-06	2.32e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GSTA2—liver cancer	3e-06	2.32e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MAPK8—liver cancer	2.97e-06	2.3e-05	CbGpPWpGaD
Dexamethasone—CYP3A43—Metabolism—AKT1—liver cancer	2.96e-06	2.29e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—CYP1A1—liver cancer	2.95e-06	2.28e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CYCS—liver cancer	2.9e-06	2.24e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GSTA1—liver cancer	2.9e-06	2.24e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—CYP1A1—liver cancer	2.89e-06	2.23e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—CYP1A1—liver cancer	2.88e-06	2.23e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—GSTM1—liver cancer	2.87e-06	2.22e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—APC—liver cancer	2.87e-06	2.22e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—GSTP1—liver cancer	2.87e-06	2.21e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PIK3CG—liver cancer	2.86e-06	2.21e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—NAT2—liver cancer	2.86e-06	2.21e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—MTHFR—liver cancer	2.86e-06	2.21e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	2.86e-06	2.21e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CYP2E1—liver cancer	2.85e-06	2.2e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—GOT1—liver cancer	2.85e-06	2.2e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—GGT1—liver cancer	2.85e-06	2.2e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CYCS—liver cancer	2.83e-06	2.19e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CYP2E1—liver cancer	2.83e-06	2.18e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—HMOX1—liver cancer	2.83e-06	2.18e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PPARA—liver cancer	2.81e-06	2.17e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—GOT1—liver cancer	2.78e-06	2.15e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—GGT1—liver cancer	2.78e-06	2.15e-05	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—PIK3CA—liver cancer	2.77e-06	2.14e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PIK3CD—liver cancer	2.77e-06	2.14e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PPARG—liver cancer	2.76e-06	2.13e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PIK3CB—liver cancer	2.76e-06	2.13e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—MTHFR—liver cancer	2.75e-06	2.12e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PIK3CD—liver cancer	2.75e-06	2.12e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ALDOB—liver cancer	2.75e-06	2.12e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—VEGFA—liver cancer	2.74e-06	2.12e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.74e-06	2.12e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—ALB—liver cancer	2.74e-06	2.11e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—STAT3—liver cancer	2.72e-06	2.1e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—ALB—liver cancer	2.71e-06	2.09e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—BRAF—liver cancer	2.7e-06	2.08e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PPARA—liver cancer	2.7e-06	2.08e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—MTHFR—liver cancer	2.69e-06	2.08e-05	CbGpPWpGaD
Dexamethasone—PGR—Gene Expression—AKT1—liver cancer	2.69e-06	2.08e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—MTHFR—liver cancer	2.69e-06	2.08e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CYCS—liver cancer	2.67e-06	2.06e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PIK3CB—liver cancer	2.66e-06	2.05e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CYCS—liver cancer	2.65e-06	2.04e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PPARA—liver cancer	2.64e-06	2.04e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PPARA—liver cancer	2.64e-06	2.04e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—GSTM1—liver cancer	2.63e-06	2.03e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GOT1—liver cancer	2.62e-06	2.02e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GGT1—liver cancer	2.62e-06	2.02e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CRABP1—liver cancer	2.62e-06	2.02e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GGT1—liver cancer	2.6e-06	2.01e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GOT1—liver cancer	2.6e-06	2.01e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—GSTP1—liver cancer	2.56e-06	1.98e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—MTHFR—liver cancer	2.54e-06	1.96e-05	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—PIK3CA—liver cancer	2.54e-06	1.96e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—MYC—liver cancer	2.53e-06	1.95e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—PIK3CD—liver cancer	2.52e-06	1.95e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—HMOX1—liver cancer	2.52e-06	1.95e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.52e-06	1.95e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—TGFB1—liver cancer	2.52e-06	1.95e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PIK3CD—liver cancer	2.52e-06	1.94e-05	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—PIK3CA—liver cancer	2.51e-06	1.94e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—GSTP1—liver cancer	2.5e-06	1.93e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—CYP1A1—liver cancer	2.5e-06	1.93e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—SERPINE1—liver cancer	2.5e-06	1.93e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PPARA—liver cancer	2.49e-06	1.92e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—ALB—liver cancer	2.49e-06	1.92e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—HMOX1—liver cancer	2.46e-06	1.9e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PIK3CB—liver cancer	2.42e-06	1.87e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PIK3CG—liver cancer	2.4e-06	1.86e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PIK3CB—liver cancer	2.39e-06	1.85e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GSTP1—liver cancer	2.35e-06	1.82e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—GSTM1—liver cancer	2.35e-06	1.82e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—KRAS—liver cancer	2.33e-06	1.8e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GSTP1—liver cancer	2.33e-06	1.8e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—MTHFR—liver cancer	2.33e-06	1.8e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—HMOX1—liver cancer	2.32e-06	1.79e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PPARG—liver cancer	2.32e-06	1.79e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PIK3CG—liver cancer	2.31e-06	1.78e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—HMOX1—liver cancer	2.3e-06	1.78e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—GSTM1—liver cancer	2.3e-06	1.77e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—HPGDS—liver cancer	2.29e-06	1.77e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PPARA—liver cancer	2.28e-06	1.76e-05	CbGpPWpGaD
Dexamethasone—CYP17A1—Metabolism—AKT1—liver cancer	2.27e-06	1.75e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PIK3CG—liver cancer	2.26e-06	1.75e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PIK3CG—liver cancer	2.26e-06	1.74e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—RAF1—liver cancer	2.25e-06	1.74e-05	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—MYC—liver cancer	2.25e-06	1.73e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.24e-06	1.73e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PPARG—liver cancer	2.23e-06	1.72e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—CYP1A1—liver cancer	2.23e-06	1.72e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—PIK3CA—liver cancer	2.23e-06	1.72e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—MTOR—liver cancer	2.2e-06	1.7e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—PIK3CB—liver cancer	2.2e-06	1.7e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PIK3CB—liver cancer	2.19e-06	1.69e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PPARG—liver cancer	2.18e-06	1.69e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PPARG—liver cancer	2.18e-06	1.68e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—CYP1A1—liver cancer	2.18e-06	1.68e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—GSTM1—liver cancer	2.16e-06	1.67e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—GSTM1—liver cancer	2.14e-06	1.66e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—PIK3CA—liver cancer	2.14e-06	1.66e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PIK3CG—liver cancer	2.13e-06	1.65e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PIK3CD—liver cancer	2.11e-06	1.63e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—ALB—liver cancer	2.09e-06	1.61e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—MTHFR—liver cancer	2.08e-06	1.6e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—TP53—liver cancer	2.07e-06	1.6e-05	CbGpPWpGaD
Dexamethasone—CYP11A1—Metabolism—AKT1—liver cancer	2.07e-06	1.6e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CDKN1B—liver cancer	2.06e-06	1.59e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PPARG—liver cancer	2.06e-06	1.59e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.05e-06	1.58e-05	CbGpPWpGaD
Dexamethasone—CYP4A11—Metabolism—AKT1—liver cancer	2.05e-06	1.58e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—CYP1A1—liver cancer	2.05e-06	1.58e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PSMA4—liver cancer	2.04e-06	1.58e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PSMD10—liver cancer	2.04e-06	1.58e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PPARA—liver cancer	2.04e-06	1.57e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—CYP1A1—liver cancer	2.03e-06	1.57e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PIK3CD—liver cancer	2.03e-06	1.57e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—MTHFR—liver cancer	2.03e-06	1.57e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—ALB—liver cancer	2.01e-06	1.55e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PPARA—liver cancer	1.99e-06	1.54e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PIK3CD—liver cancer	1.99e-06	1.54e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PIK3CD—liver cancer	1.99e-06	1.53e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GOT2—liver cancer	1.98e-06	1.53e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—HRAS—liver cancer	1.98e-06	1.53e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—ALB—liver cancer	1.96e-06	1.52e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—ALB—liver cancer	1.96e-06	1.51e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PIK3CG—liver cancer	1.96e-06	1.51e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CTNNB1—liver cancer	1.95e-06	1.51e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—MTHFR—liver cancer	1.91e-06	1.48e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—CDKN1A—liver cancer	1.91e-06	1.47e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—IL6—liver cancer	1.9e-06	1.47e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—MTHFR—liver cancer	1.9e-06	1.46e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PPARG—liver cancer	1.89e-06	1.46e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PIK3CD—liver cancer	1.88e-06	1.45e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PPARA—liver cancer	1.88e-06	1.45e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CYP2E1—liver cancer	1.87e-06	1.44e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—PIK3CA—liver cancer	1.86e-06	1.44e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PPARA—liver cancer	1.86e-06	1.44e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—ALB—liver cancer	1.85e-06	1.43e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PIK3CB—liver cancer	1.84e-06	1.42e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.83e-06	1.41e-05	CbGpPWpGaD
Dexamethasone—ABCB11—Metabolism—AKT1—liver cancer	1.82e-06	1.41e-05	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PIK3CB—liver cancer	1.77e-06	1.37e-05	CbGpPWpGaD
Dexamethasone—PGR—Signaling Pathways—AKT1—liver cancer	1.75e-06	1.35e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PIK3CG—liver cancer	1.75e-06	1.35e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CYCS—liver cancer	1.75e-06	1.35e-05	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PIK3CB—liver cancer	1.73e-06	1.34e-05	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PIK3CB—liver cancer	1.73e-06	1.34e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PIK3CD—liver cancer	1.72e-06	1.33e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GGT1—liver cancer	1.71e-06	1.32e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GOT1—liver cancer	1.71e-06	1.32e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PIK3CG—liver cancer	1.7e-06	1.32e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—STAT3—liver cancer	1.7e-06	1.31e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—ALB—liver cancer	1.7e-06	1.31e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PPARG—liver cancer	1.69e-06	1.3e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—PIK3CA—liver cancer	1.68e-06	1.3e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.67e-06	1.29e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PPARG—liver cancer	1.64e-06	1.27e-05	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PIK3CB—liver cancer	1.64e-06	1.26e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—PIK3CA—liver cancer	1.62e-06	1.25e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PIK3CG—liver cancer	1.61e-06	1.24e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PIK3CG—liver cancer	1.59e-06	1.23e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—MYC—liver cancer	1.58e-06	1.22e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—TGFB1—liver cancer	1.58e-06	1.22e-05	CbGpPWpGaD
Dexamethasone—NR3C1—Gene Expression—AKT1—liver cancer	1.56e-06	1.2e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PPARG—liver cancer	1.55e-06	1.2e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GSTP1—liver cancer	1.54e-06	1.19e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PPARG—liver cancer	1.54e-06	1.19e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PIK3CD—liver cancer	1.54e-06	1.19e-05	CbGpPWpGaD
Dexamethasone—SLCO1A2—Metabolism—AKT1—liver cancer	1.52e-06	1.17e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—HMOX1—liver cancer	1.52e-06	1.17e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—ALB—liver cancer	1.52e-06	1.17e-05	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PIK3CB—liver cancer	1.5e-06	1.16e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PIK3CD—liver cancer	1.5e-06	1.16e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—ALB—liver cancer	1.48e-06	1.14e-05	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—PIK3CA—liver cancer	1.47e-06	1.14e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—KRAS—liver cancer	1.46e-06	1.13e-05	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—PIK3CA—liver cancer	1.46e-06	1.13e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—GSTM1—liver cancer	1.41e-06	1.09e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PIK3CD—liver cancer	1.41e-06	1.09e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PIK3CD—liver cancer	1.4e-06	1.08e-05	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—ALB—liver cancer	1.39e-06	1.08e-05	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—ALB—liver cancer	1.38e-06	1.07e-05	CbGpPWpGaD
Dexamethasone—CYP19A1—Metabolism—AKT1—liver cancer	1.37e-06	1.06e-05	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—PIK3CA—liver cancer	1.34e-06	1.04e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—CYP1A1—liver cancer	1.34e-06	1.04e-05	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PIK3CB—liver cancer	1.34e-06	1.03e-05	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—PIK3CA—liver cancer	1.34e-06	1.03e-05	CbGpPWpGaD
Dexamethasone—CYP1B1—Metabolism—AKT1—liver cancer	1.32e-06	1.02e-05	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PIK3CB—liver cancer	1.31e-06	1.01e-05	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—MTHFR—liver cancer	1.25e-06	9.65e-06	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—HRAS—liver cancer	1.24e-06	9.58e-06	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PIK3CB—liver cancer	1.23e-06	9.5e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PPARA—liver cancer	1.23e-06	9.47e-06	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PIK3CB—liver cancer	1.22e-06	9.42e-06	CbGpPWpGaD
Dexamethasone—ABCG2—Metabolism—AKT1—liver cancer	1.2e-06	9.29e-06	CbGpPWpGaD
Dexamethasone—CYP3A7—Metabolism—AKT1—liver cancer	1.19e-06	9.21e-06	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—IL6—liver cancer	1.19e-06	9.17e-06	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—PIK3CA—liver cancer	1.12e-06	8.67e-06	CbGpPWpGaD
Dexamethasone—PTGS2—Disease—AKT1—liver cancer	1.1e-06	8.46e-06	CbGpPWpGaD
Dexamethasone—CYP2A6—Metabolism—AKT1—liver cancer	1.09e-06	8.44e-06	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—PIK3CA—liver cancer	1.08e-06	8.34e-06	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—PIK3CA—liver cancer	1.06e-06	8.16e-06	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—PIK3CA—liver cancer	1.06e-06	8.15e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PIK3CG—liver cancer	1.05e-06	8.11e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PPARG—liver cancer	1.01e-06	7.83e-06	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—PIK3CA—liver cancer	9.97e-07	7.7e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PIK3CD—liver cancer	9.23e-07	7.13e-06	CbGpPWpGaD
Dexamethasone—PTGS2—Metabolism—AKT1—liver cancer	9.17e-07	7.08e-06	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—PIK3CA—liver cancer	9.14e-07	7.06e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—ALB—liver cancer	9.11e-07	7.04e-06	CbGpPWpGaD
Dexamethasone—CYP2B6—Metabolism—AKT1—liver cancer	8.82e-07	6.81e-06	CbGpPWpGaD
Dexamethasone—CYP2E1—Metabolism—AKT1—liver cancer	8.64e-07	6.67e-06	CbGpPWpGaD
Dexamethasone—CYP3A5—Metabolism—AKT1—liver cancer	8.62e-07	6.66e-06	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—PIK3CA—liver cancer	8.16e-07	6.3e-06	CbGpPWpGaD
Dexamethasone—CYP1A1—Metabolism—AKT1—liver cancer	8.14e-07	6.29e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PIK3CB—liver cancer	8.05e-07	6.21e-06	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—PIK3CA—liver cancer	7.96e-07	6.15e-06	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—PIK3CA—liver cancer	7.5e-07	5.79e-06	CbGpPWpGaD
Dexamethasone—CYP2C8—Metabolism—AKT1—liver cancer	7.47e-07	5.76e-06	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—PIK3CA—liver cancer	7.44e-07	5.74e-06	CbGpPWpGaD
Dexamethasone—CYP2C19—Metabolism—AKT1—liver cancer	6.66e-07	5.15e-06	CbGpPWpGaD
Dexamethasone—ABCB1—Metabolism—AKT1—liver cancer	6.5e-07	5.02e-06	CbGpPWpGaD
Dexamethasone—CYP2D6—Metabolism—AKT1—liver cancer	6.13e-07	4.73e-06	CbGpPWpGaD
Dexamethasone—CYP2C9—Metabolism—AKT1—liver cancer	6.08e-07	4.69e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—PIK3CA—liver cancer	4.91e-07	3.79e-06	CbGpPWpGaD
Dexamethasone—CYP3A4—Metabolism—AKT1—liver cancer	4.01e-07	3.09e-06	CbGpPWpGaD
